OBJECTIVE: To develop a definition of global flare in juvenile systemic lupus erythematosus (SLE) and derive candidate criteria for measuring juvenile SLE flares. METHODS: Pediatric rheumatologists answered 2 Delphi questionnaires to achieve consensus on a common definition of juvenile SLE flare and identify variables for use in candidate flare criteria. The diagnostic accuracy of these candidate flare criteria was tested with data from juvenile SLE patients (n = 98; 623 visits total). Physician-rated change in the juvenile SLE course (worsening, yes/no) between visits served as the criterion standard. RESULTS: There was 96% consensus that a "a flare is a measurable worsening of juvenile SLE disease activity in at least one organ system, involving new or worse signs of disease that may be accompanied by new or worse SLE symptoms. Depending on the severity of the flare, more intensive therapy may be required." Variables suggested for use in flare criteria were: physician-rated disease activity (V1), patient well-being, protein:creatinine ratio, a validated disease activity index (V2), the Child Health Questionnaire physical summary score (V3), anti-double-stranded DNA antibodies, erythrocyte sedimentation rate, and complement levels. Using multiple logistic regression, several candidate flare criteria were derived with area under the receiver operating characteristic curve (AUC) as high as 0.92 (sensitivity >or=85%, specificity >or=85%); classification and regression tree analysis suggested that V1, V2, and V3 suffice to identify juvenile SLE flares (AUC 0.81; sensitivity = 64%, specificity = 86%). CONCLUSION: Consensus about a definition of global disease flare for juvenile SLE has been obtained and promising candidate flare criteria have been developed. These will need further assessment of their ease of use and accuracy in prospective study.
OBJECTIVE: To develop a definition of global flare in juvenile systemic lupus erythematosus (SLE) and derive candidate criteria for measuring juvenile SLE flares. METHODS: Pediatric rheumatologists answered 2 Delphi questionnaires to achieve consensus on a common definition of juvenile SLE flare and identify variables for use in candidate flare criteria. The diagnostic accuracy of these candidate flare criteria was tested with data from juvenile SLEpatients (n = 98; 623 visits total). Physician-rated change in the juvenile SLE course (worsening, yes/no) between visits served as the criterion standard. RESULTS: There was 96% consensus that a "a flare is a measurable worsening of juvenile SLE disease activity in at least one organ system, involving new or worse signs of disease that may be accompanied by new or worse SLE symptoms. Depending on the severity of the flare, more intensive therapy may be required." Variables suggested for use in flare criteria were: physician-rated disease activity (V1), patient well-being, protein:creatinine ratio, a validated disease activity index (V2), the Child Health Questionnaire physical summary score (V3), anti-double-stranded DNA antibodies, erythrocyte sedimentation rate, and complement levels. Using multiple logistic regression, several candidate flare criteria were derived with area under the receiver operating characteristic curve (AUC) as high as 0.92 (sensitivity >or=85%, specificity >or=85%); classification and regression tree analysis suggested that V1, V2, and V3 suffice to identify juvenile SLE flares (AUC 0.81; sensitivity = 64%, specificity = 86%). CONCLUSION: Consensus about a definition of global disease flare for juvenile SLE has been obtained and promising candidate flare criteria have been developed. These will need further assessment of their ease of use and accuracy in prospective study.
Authors: C Gordon; D Jayne; C Pusey; D Adu; Z Amoura; M Aringer; J Ballerin; R Cervera; J Calvo-Alén; C Chizzolini; Jm Dayer; A Doria; F Ferrario; J Floege; L Guillevin; M Haubitz; F Hiepe; F Houssiau; P Lesavre; L Lightstone; Pl Meroni; O Meyer; B Moulin; K O'Reilly; M Praga; H Schulze-Koops; Ra Sinico; Kgc Smith; A Tincani; C Vasconcelos; G Hughes Journal: Lupus Date: 2009-03 Impact factor: 2.911
Authors: W Bencivelli; C Vitali; D A Isenberg; J S Smolen; M L Snaith; M Sciuto; S Bombardieri Journal: Clin Exp Rheumatol Date: 1992 Sep-Oct Impact factor: 4.473
Authors: Hermine I Brunner; Gloria C Higgins; Kristina Wiers; Sivia K Lapidus; Judyann C Olson; Karen Onel; Marilynn Punaro; Jun Ying; Marisa S Klein-Gitelman; Michael Seid Journal: J Rheumatol Date: 2009-06-01 Impact factor: 4.666
Authors: Michelle Petri; Nuntana Kasitanon; Sukminder Singh; Kimberly Link; Laurence Magder; Sang-Cheol Bae; John G Hanly; Ola Nived; Gunnar Sturfelt; Ronald van Vollenhoven; Daniel J Wallace; Graciela S Alarcón; Dwomoa Adu; Carmen Avila-Casado; Sasha R Bernatsky; Ian N Bruce; Ann E Clarke; Gabriel Contreras; Derek M Fine; Dafna D Gladman; Caroline Gordon; Kenneth C Kalunian; Michael P Madaio; Brad H Rovin; Jorge Sanchez-Guerrero; Kristjan Steinsson; Cynthia Aranow; James E Balow; Jill P Buyon; Ellen M Ginzler; Munther A Khamashta; Murray B Urowitz; Mary Anne Dooley; Joan T Merrill; Rosalind Ramsey-Goldman; Josef Font; James Tumlin; Thomas Stoll; Asad Zoma Journal: Arthritis Rheum Date: 2008-06
Authors: Hermine I Brunner; Rina Mina; Clarissa Pilkington; Michael W Beresford; Andreas Reiff; Deborah M Levy; Lori B Tucker; B Anne Eberhard; Angelo Ravelli; Laura E Schanberg; Claudia Saad-Magalhaes; Gloria C Higgins; Karen Onel; Nora G Singer; Emily von Scheven; Lukasz Itert; Marisa S Klein-Gitelman; Marilynn Punaro; Jun Ying; Edward H Giannini Journal: Arthritis Care Res (Hoboken) Date: 2011-09 Impact factor: 4.794
Authors: R Mina; M S Klein-Gitelman; S Nelson; B A Eberhard; G Higgins; N G Singer; K Onel; L Tucker; K M O'Neil; M Punaro; D M Levy; K Haines; J Ying; H I Brunner Journal: Lupus Date: 2014-10-21 Impact factor: 2.911
Authors: Rina Mina; Marisa S Klein-Gitelman; Angelo Ravelli; Michael W Beresford; Tadej Avcin; Graciela Espada; B Anne Eberhard; Laura E Schanberg; Kathleen M O'Neil; Clovis A Silva; Gloria C Higgins; Karen Onel; Nora G Singer; Emily von Scheven; Lisa F Imundo; Shannen Nelson; Edward H Giannini; Hermine I Brunner Journal: Arthritis Care Res (Hoboken) Date: 2012-05 Impact factor: 4.794
Authors: Hermine I Brunner; Michael J Holland; Michael W Beresford; Stacy P Ardoin; Simone Appenzeller; Clovis A Silva; Francisco Flores; Beatrice Goilav; Pinar Ozge Avar Aydin; Scott E Wenderfer; Deborah M Levy; Angelo Ravelli; Raju Khubchandani; Tadej Avcin; Marisa S Klein-Gitelman; Nicolino Ruperto; Brian M Feldman; Jun Ying Journal: Arthritis Care Res (Hoboken) Date: 2019-05 Impact factor: 4.794
Authors: Hermine I Brunner; Michael Holland; Michael W Beresford; Stacy P Ardoin; Simone Appenzeller; Clovis A Silva; Francisco Flores; Beatrice Goilav; Scott E Wenderfer; Deborah M Levy; Angelo Ravelli; Raju Khunchandani; Tadej Avcin; Marisa S Klein-Gitelman; Brian M Feldman; Nicolino Ruperto; Jun Ying Journal: Arthritis Care Res (Hoboken) Date: 2018-04-25 Impact factor: 4.794
Authors: Jennifer N Stinson; Mark Connelly; Lindsay A Jibb; Laura E Schanberg; Gary Walco; Lynn R Spiegel; Shirley Ml Tse; Elizabeth C Chalom; Peter Chira; Michael Rapoff Journal: Pediatr Rheumatol Online J Date: 2012-04-10 Impact factor: 3.054
Authors: Karine Toupin April; Jennifer Stinson; Heather Boon; Ciarán M Duffy; Adam M Huber; Michele Gibbon; Martin Descarreaux; Lynn Spiegel; Sunita Vohra; Peter Tugwell Journal: PLoS One Date: 2016-03-10 Impact factor: 3.240